GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Growth hormone (GH) responses to the combined administration of GH-releasing hormone plus GH-releasing peptide 6 in adults with GH deficiency.
Leal-Cerro. A A; Garcia. E E; Astorga. R R; Casanueva. F F FF; Dieguez. C C
Key Findings
- Combined IV GHRH + GHRP‑6 produced a clear GH surge in roughly 40% of growth‑hormone‑deficient adults.
- The remaining 60% had a minimal GH rise (peak < 10 mU/L), indicating a mixed responsiveness.
- Standard GH tests may not fully capture who will respond to this peptide combination.
Practical Outcomes
- For biohackers, the data suggest that GHRP‑6 alone is not a guaranteed GH booster; it may work better when paired with GHRH, but only in a subset of people with true GH deficiency. The study used intravenous dosing, which differs from the sub‑cutaneous routes most enthusiasts use, so direct protocol translation is limited. Overall, the findings provide modest insight into who might benefit from combined therapy, but they do not offer a ready‑to‑use regimen for healthy individuals.
Summary
In adults who have a diagnosed lack of growth hormone, giving a mix of two hormones—GHRH and GHRP‑6—raised GH levels in about 40% of the participants, while the other 60% showed little change. The test used a small IV dose (1 µg/kg) of each peptide and the response varied widely.
Abstract
In recent years the health problems of adults with growth hormone deficiency (GHD) and the benefits of GH replacement therapy have received considerable attention. However, the reliability of conventional GH tests in the assessment of pituitary GH reserve in this group of patients is still controversial. In this study, we assessed GH secretion after the combined administration of GH-releasing hormone (GHRH) (1 microgram/kg iv) and GH-releasing peptide 6 (GHRP-6, 1 microgram/kg iv) in adult patients diagnosed with GHD by conventional GH testing, and correlate this response with insulin-like growth factor I levels. Twenty-one subjects (13 male, 8 female) with long-standing diagnosis of GHD aged 21-54 years were studied. In 13 subjects GH responses to GHRH plus GHRP-6 were markedly reduced (peak GH response < 10 mU/l), whereas in the remaining eight the response was greater (range 11-100 mU/l). In conclusion, our data show that combined administration of GHRH plus GHRP-6 elicited a significant increase in plasma GH levels in about 40% of patients diagnosed with GHD by conventional GH testing.
Study Information
pubmed
1995
10.1530/eje.0.1320712